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7.72 DDD/1000 inh/day or 39.33%. However the amount of funding spent in this 
group of drugs was decreased for 12,850,895.28€ or 14.18%. This research was 
supported by Provincial Secretariat for Science and Technological Development, 
Autonomous Province of Vojvodina project No 114-451-2458/2011 and by 
Ministry of Science and Technological Development, Republic of Serbia project 
No 41012.  
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OBJECTIVES: Following solid organ transplantation (SOT) or hematopoietic stem 
cell transplantation (HSCT), patients are at risk of cytomegalovirus (CMV) 
disease. The impact of CMV disease on mortality, graft rejection, hospitalisation 
costs and on the probability of transplant rejection, failure or Graft versus Host 
Disease (GVHD) and other adverse events was estimated. METHODS: A 
retrospective cohort study of a database of hospitalisations in France (PMSI) from 
2007 to 2011 was conducted. Logistic regression was used to estimate the impact 
of CMV disease during initial hospitalisation on the probability of graft rejection 
and mortality over one year, adjusting for age, gender and comorbidities. The 
impact of CMV disease on costs and on length of stay (LOS) was estimated using 
generalised linear modeling, a correction for endogeneity was performed 
afterwards. RESULTS: Among 20,473 SOT and 18,809 HSCT recipients, CMV 
disease was reported in 9.72% and 6.65% of cases respectively. CMV disease was 
associated with a significant increase in mortality (SOT-patients: odds ratio=1.46, 
p=0.0552; HSCT-patients: OR=4.00, p<.0001). Patients with CMV disease at initial 
hospitalisation were more likely to experience graft rejection, failure or GVHD 
(SOT: OR =1.663, p= 0.0005; HSCT: OR=2.605, p <.0001). CMV was related to higher 
LOS and higher costs at initial stay for both subgroups (SOT: 8.7-days, €4,134, 
p<0.0001; HSCT: 8.75-days, €22,252, p<0.0001). The difference in total 
hospitalisation costs over 2 years between patients with and without CMV was 
€13,159 and €32,691 for SOT and HSCT recipients respectively. CMV disease was 
strongly associated with pneumonia (SOT: OR=3.37; HSCT: OR=3.37) and with 
enteritis (SOT: OR=3.63; HSCT: OR=3.90). CONCLUSIONS: CMV disease is 
associated with substantial increases in probability of graft rejection, mortality, 
length of stay, adverse events and hospitalisation costs in French transplant 
recipients. A limitation of this study is that it was not possible to adjust for the 
intensity of immunosuppressive therapy.  
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OBJECTIVES: Although effective chemotherapy is available, tuberculosis (TB) 
remains a major public health problem worldwide. The current study aimed to 
determine the prevalence of pulmonary TB and multi-drug resistant (MDR) TB in 
Baghdad, Iraq. METHODS: Databases of Thoracic and Respiratory Diseases 
Specialist Center were retrospectively reviewed to determine the prevalence of 
pulmonary TB in Baghdad. This center is the largest center for the diagnosis, 
treatment and recording of all new and previously treated TB cases in Baghdad 
and the other states of Iraq. All newly diagnosed TB patients who registered for 
TB treatment between January 1, 2011 and June 30, 2012 were included in the 
analysis. RESULTS: A total of 2968 TB cases were newly registered in Baghdad 
during the period under review. Of these, 1188 cases were smear positive 
pulmonary TB. The prevalence of smear positive and smear negative pulmonary 
TB in Baghdad were 40.02% (95% CI 34.46%-45.58%) and 16.81% (95% CI 12.56%-
21.06%) respectively. Additionally, 1810 of the newly diagnosed TB cases were 
male and 1158 were female. Baghdad accounted for 25.58% (95% CI 21.61%-
29.55%) of the estimated prevalence of smear positive pulmonary TB of the 
country. Furthermore, 103 laboratory-confirmed MDR-TB of new cases were 
reported in Baghdad during the same period. The estimated prevalence of MDR-
TB among newly diagnosed TB cases was 3.47% (95% CI 1.51%-5.43%). 
CONCLUSIONS: The results of the current study will have a significant 
implication for strengthening the TB control program in the capital Baghdad. In 
addition, actions to expand and plan the appropriate diagnostic and treatment 
services for patients with MDR-TB are warranted.  
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OBJECTIVES: To evaluate advanced liver disease outcomes of Medicare 
beneficiaries diagnosed with chronic hepatitis C virus (HCV). METHODS: This 
study was based on 2005-2010 CMS Fee-for-Service Medicare longitudinal claims 
data which includes 100% of the adjudicated medical claims for all inpatient and 
outpatient institutional providers and a 5% sample of adjudicated patient claims 
from the physician office setting. ICD-9 codes were used to identify patients with 
chronic HCV and advanced liver disease outcomes. Disease prevalence and 
trends over time were examined. RESULTS: In 2010, the prevalence rates of 
advanced liver disease such as non-decompensated liver disease (26.5% versus 
0.4%), decompensated cirrhosis (20.8% versus 1.6%), hepatocellular carcinoma 
(4.3% versus 0.1%), liver transplant (3.6% versus 0.06%), were higher (all 
statistically significant, p<0.0001) in the chronic HCV population than the non-
HCV population. Prevalence rates of complications remained stable across the 
six year period, with the exception of decompensated cirrhosis, the prevalence of 
which increased from 15.0% to 20.8% for chronic HCV patients and 0.6% to 1.6% 
in non-HCV patients. CONCLUSIONS: Evaluation of Medicare beneficiaries 
indicates that chronic HCV patients have a greater prevalence of advanced liver 
disease compared with non-HCV patients. The 6-year prevalence trend of 
decompensated cirrhosis has increased for both chronic HCV patients and non-
HCV patients.  
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OBJECTIVES: To characterize the demographics and comorbidities of US 
Medicare beneficiaries diagnosed with chronic hepatitis C virus (HCV) infection. 
METHODS: This study was based on 2005-2010 CMS Fee-for-Service Medicare 
longitudinal claims data which includes 100% of the adjudicated medical claims 
for all inpatient and outpatient institutional providers and a 5% sample of 
adjudicated patient claims from the physician office setting. ICD-9 codes were 
used to identify patients diagnosed with chronic HCV infection as well as the 
following comorbidities: anxiety, depression, alcohol abuse, HIV, and end stage 
renal disease (ESRD). RESULTS: A total of 368,871 chronic HCV patients were 
identified as having received Medicare benefits between 2005 and 2010. The 
average age of these chronic HCV patients in 2010 was 57.2 (SD=11.7) which is 14 
years younger than the non-HCV Medicare population (average = 71.0, SD=13.0). 
Only 28.4% of chronic HCV patients qualified for Medicare due to age alone (≥65 
years old) versus 82.0% of non-HCV patients. The majority of chronic HCV 
patients (63.4%) qualified for Medicare due to a disability that excludes ESRD, 
while only 16.9% of non-HCV patients met the same criteria. Chronic HCV 
patients exhibited a wide array of health problems. The prevalence rates of 
comorbidities such as anxiety (15.2% vs. 4.8%), depression (26.8% vs. 7.6%), 
alcohol abuse (40.9% vs. 2.1%), HIV (8.1% vs. 0.3%) and ESRD (8.5% versus 1.3%) 
were higher (all statistically significant, p<0.0001) in the chronic HCV population 
than the non-HCV population. CONCLUSIONS: Medicare beneficiaries are often 
generalized as over 65 years of age, but chronic HCV Medicare patients are 
typically younger and qualify for Medicare due to disability. The burden of 
patients with chronic HCV on Medicare is further exacerbated by the high 
prevalence of other costly comorbidities.  
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OBJECTIVES: To evaluate the prevalence of advanced liver disease outcomes 
within a large US database of commercially-insured individuals diagnosed with 
chronic hepatitis C virus (HCV) infection. METHODS: This study was based on 
2007-2011 IMS LifeLink claims data which includes adjudicated health claims 
data for 74 million patients and over 75 commercial health plans. ICD-9 codes 
were used to identify patients with chronic HCV and advanced liver disease 
outcomes. Trends in prevalence of these outcomes over time were also 
examined. RESULTS: In 2011, the prevalence rates of advanced liver disease such 
as non-decompensated liver disease (20.48% vs. 0.10%), decompensated cirrhosis 
(15.11% vs. 0.46%), hepatocellular carcinoma (3.43% vs. 0.03%), liver transplant 
(2.58% vs. 0.01%), were higher (all statistically significant, p<0.0001) in the 
chronic HCV population than the non-HCV population. Five-year prevalence 
trends of complications stayed stable, with the exception of decompensated 
cirrhosis and hepatocellular carcinoma. The prevalence of decompensated 
cirrhosis increased from 11.16% to 15.11% for chronic HCV patients and 0.31% to 
0.46% in non-HCV patients. The prevalence of hepatocellular carcinoma 
increased from 2.3% to 3.43% for chronic HCV patients and 0.02% to 0.03% in 
non-HCV patients. CONCLUSIONS: Evaluation of a large US database of 
commercially-insured individuals indicates that chronic HCV patients have a 
greater prevalence of advanced liver disease compared with non-HCV patients. 
The 5-year prevalence trend of decompensated cirrhosis has increased for both 
chronic HCV patients and non-HCV patients.  
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OBJECTIVES: To characterize the demographics and comorbidities of patients 
diagnosed with chronic hepatitis C virus (HCV) infection reporting claims to a 
large US database of commercially-insured individuals. METHODS: This study 
was based on 2007-2011 IMS LifeLink claims data which includes adjudicated 
health claims data for 74 million patients and over 75 commercial health plans. 
